Most gallstones originate from cholesterol-supersaturated bile. Statins inhibit hepatic cholesterol biosynthesis and therefore may reduce the risk of gallstone disease. Population-based evidence, however, is sparse. Thus, the authors conducted a population-based case-control study using medical databases from northern Denmark (1.7 million inhabitants) to identify 32,494 cases of gallstones occurring between 1996 and 2008 and to identify age-, sex-, and county-matched population controls for each case. Cases and their matched controls who were exposed to lipid-lowering drugs were categorized as current users if their last prescription was redeemed 90 days before the case's diagnosis date; otherwise, they were categorized as former users. Conditional logistic regression was used to estimate adjusted odds ratios and 95% confidence intervals for gallstone disease in patients treated with lipid-lowering drugs. In current users, the adjusted odds ratios associating statin use with the occurrence of gallstone disease were 1.17 (95% confidence interval (CI): 1.06, 1.30) for those who had 1-4 prescriptions, 0.89 (95% CI: 0.80, 0.97) for those who had 5-19 prescriptions, and 0.76 (95% CI: 0.69, 0.84) for those who had 20 total prescriptions. In former users, the corresponding adjusted odds ratios were 1.24 (95% CI: 1.11, 1.39), 0.97 (95% CI: 0.86, 1.10), and 0.79 (95% CI: 0.64, 0.97), respectively. The use of other lipid-lowering drugs showed no similar association.
The prevalence of gallstone disease in the Western world ranges from 6% to 50%, increasing with age and varying with geographic region (1) . The risk increases with certain genetic factors, increasing age, female gender, and obesity (1, 2) . Gallstone disease is a chronic and usually asymptomatic condition, but it leads to severe complications in about 2% of symptomatic patients (3) . Intense pain in the upper quadrant of the abdomen and acute cholecystitis are the most common complications and may require surgical removal of the gallbladder (cholecystectomy). Jaundice, pancreatitis, and cholangitis caused by stones that migrate from the gallbladder to the common bile duct are other severe complications (3) . In the Western world, 80%-90% of gallstones originate from cholesterol-supersaturated bile, with the remainder formed as pigment stones, primarily from bilirubin and calcium (4) .
In the liver, 3-hydroxy-3-methylglutaryl coenzyme A inhibitors (statins) inhibit cholesterol biosynthesis, and thus may prevent gallstone formation, gallstone recurrence, subsequent complications, and cholecystectomy. Evidence of the association between statins and gallstone disease is conflicting (5), although 3 recent studies-a US cohort study (6) and case-control studies from United Kingdom (7) and Israel (8)-have shown a reduced risk of gallstone disease followed by cholecystectomy in people taking statins. These studies estimated the association between statins and severe gallstone disease only. In addition, the US study was based on questionnaire reports of gallstone disease and statin use, the UK study relied on information from general practitioners regarding in-hospital treatments (6, 7, 9) , and the Israeli study lacked details of important covariates (8) . There is, therefore, a need for evidence evaluating the association between statin use and the occurrence of more general gallstone disease in an unselected population (10, 11) . To address these limitations, we conducted a study using Danish population-based health registries with hospitalbased information to evaluate the association between statin use (including intensity and duration) and gallstone disease.
MATERIALS AND METHODS

Source population and setting
We conducted this population-based case-control study from 1996 to 2008 using medical databases from northern Denmark, which has a population of 1.7 million (about 30% of the Danish population) (12) . The Danish National Health Service provides tax-funded medical care for all Danish residents and partially reimburses the costs of most physician-prescribed drugs. We used the civil registration number, a personal identifier assigned to each Danish citizen at birth and to residents at immigration, to link the Danish medical databases (13) . For each hospital admission since 1977, the Danish National Registry of Patients (NRP) has recorded the civil registration number of the patient, dates of admission and discharge (outpatient and emergency admissions since 1995), surgical procedures, and up to 20 discharge diagnoses coded by doctors according to the International Classification of Diseases (ICD) (Eighth Revision until the end of 1993 and Tenth Revision thereafter) (14) .
Cases with gallstone disease
We identified first in-and outpatient hospitalizations in patients with gallstone disease between January 1, 1996, and December 31, 2008, by searching the NRP for diagnoses of gallstone disease (DK80), cholecytitis (DK81), or a procedure code for gallbladder surgery (KJKA, including cholecystectomy and drainage). We combined these codes to create 1 case definition referred to as gallstone disease, and the earliest recorded date for each case was used as the date of disease. We excluded preexisting cases of gallstone disease by searching the NRP back to 1977 (ICD-8 codes for gallstone disease: 574 and 575; procedure codes for gallbladder surgery before 1996: 47360 and 47365). We also excluded cases from the NRP if the patient had a history of liver, bile duct, or pancreatic cancer (ICD-8 codes 155-157; ICD-10 codes C22-C25) or <2 years' history in the prescription database (see below).
Population-based controls
For each case, we selected 10 population controls with no record of gallstone disease before the diagnosis date of the cases and matched them to the cases based on age, sex, and county of residence. Controls were selected from the Danish Civil Registration System, which is updated daily and has maintained records on vital statistics, dates of death, and the residences of all Danish citizens and residents since April 1, 1968 (13) . Controls were selected using risk-set sampling, and both the cases and their matched controls were assigned an index date identical to the date on which the case was diagnosed with gallstone disease.
Use of statins and other lipid-lowering drugs
Residents of northern Denmark receive prescription medications from pharmacies equipped with electronic accounting systems that are primarily used to secure reimbursement from the National Health Service (15, 16) . The pharmacies transmit the patient's civil registration number, the type and amount of drug prescribed according to the Anatomical Therapeutic Chemical classification system (Appendix Table 1 ), and the date on which the drug was dispensed to the prescription database. From the prescription database, we ascertained any use of statins before the index date. We also identified the use of fibrates, niacin, and resin, which we classified as other lipid-lowering drugs.
We classified patients as never users of lipid-lowering drugs (reference), current users if their last prescription for statins or other lipid-lowering drugs was redeemed 90 days before the index date, or former users if their last prescription was >90 days before the index date. Both current and former users were also categorized by total number of prescriptions (1-4, 5-19, and 20) .
Covariates
We collected data on potentially confounding factors from the NRP and the prescription database (17) (18) (19) (20) . We searched the NRP for any hospital records containing diagnoses of alcoholism, cancer, cardiovascular disease, chronic obstructive pulmonary disease, diabetes, hyperlipidemia, hypothyroidism, inflammatory bowel disease, liver cirrhosis, obesity, renal failure, stroke, or transient ischemic attack that occurred before the diagnosis of gallstone disease or the index date. We searched patient records in the prescription database for prescriptions for thiazides, oral antidiabetic drugs, or postmenopausal hormone (estrogen) replacement therapy (Appendix Table 1 ). We coded each of these covariates individually as a dichotomous variable (diabetes and oral antidiabetic medications were coded as a single variable).
Analysis
We calculated the frequency and proportion of cases and controls within categories of demographic characteristics, drug exposures, and covariates. We calculated odds ratios and 95% confidence intervals associating drug use with the occurrence of gallstone disease using conditional logistic regression. Because we used risk-set sampling to select controls, these odds ratios provided unbiased estimates of the corresponding incidence rate ratios (21) .
We calculated odds ratios adjusted for the covariates associating current and former use of statins or other lipidlowering drugs with the occurrence of gallstone disease, stratified by the total number of prescriptions. The reference group comprised patients with no history of using statins or other lipid-lowering drugs. These odds ratios were stratified by history of diabetes, cardiovascular disease, and obesity, and we used conventional logistic regression models because these stratified analyses required that we dissolve the matched sets. Therefore, we controlled for the matched factors as well as the other covariates.
We performed subanalyses to further explore the observed associations. First, we conducted 2 separate analyses in which we changed the cutoffs for current and former users to 30 and >30 days and 180 and >180 days, respectively, from the date of the last prescription to the index date. Second, we estimated odds ratios after changing the categorization of statins according to the time between first and last prescription before the index date (<1, 1-2, and 3 years). We stratified this analysis by intensity of statin use. We defined intensity as a measure of the number of pills prescribed divided by the total duration of use. Duration of use was determined by counting the number of days from the date of the first prescription to the index date. Using this information, we classified statin use as low-intensity (<0.5 pills/day), medium-intensity (0.5-0.8 pills/day), or high-intensity (0.9 pills/day). Third, we restricted the analysis to cases with gallbladder surgery to reduce the potential for inclusion of false-positives. Fourth, because the comparison of statin users with nonusers might be confounded by statin indications also associated with gallstone disease (e.g., obesity, hyperlipidemia, exercise, and diet), we compared statin users with a total of 5-19 and 20 prescriptions with a reference category of users with 1-4 prescriptions. Because this analysis was limited to statin users, the indications should have been more uniform. Fifth, to explore whether the associations depended on type of statin, we estimated odds ratios according to 7 statin preparation subtypes and according to lipophilicity in current and former users (lipophile: atorvastatin, cerivastatin, fluvastatin, lovastatin, and simvastatin; hydrophile: pravastatin and rosuvastatin). Last, we compared continuing statin users (i.e., those with 12 months between first and last prescription of statins and with the last prescription <12 months before the index date) with those who discontinued statins (no prescription for 12 months before their index date). Because this analysis was limited to ever users of statins, the indications should have been more uniform and included changes to diet and exercise that sometimes accompany inception of statin medications. Presumably, the behaviors would be less likely to stop at the same time as statin medication discontinuation, so a comparison of continuing statin users with those who stopped statin therapy should have been less susceptible to confounding by behavior change.
RESULTS
We identified 32,494 patients with gallstone disease (18,201 inpatients and 14,293 outpatients) and 324,925 population controls. The median age at diagnosis/index was 54.6 years, and 68.8% were women. Comorbid diseases were more frequent in cases than in controls (Table 1) . A total of 1,764 cases (5.4%) with gallstone disease and (4.8%) 15,580 controls were current statin users, yielding an overall adjusted odds ratio of 0.93 (95% confidence interval (CI): 0.87, 0.98). For current statin users, the adjusted odds ratio decreased as the overall number of prescriptions increased, from 1.17 (95% CI: 1.06, 1.30) in patients with 1-4 prescriptions to 0.76 (95% CI: 0.69, 0.84) in patients with 20 prescriptions (Table 2 ). This decrease was seen in both men and women, although women generally had higher odds ratios.
A total of 761 cases (2.3%) with gallstone disease and 5,889 (1.8 %) controls were former statin users, which corresponded to an adjusted odds ratio of 1.06 (95% CI: 0.98, 1.16) ( Table 2 ). The adjusted odds ratio decreased from 1.24 (95% CI: 1.11, 1.39) in former users with 1-4 prescriptions to 0.79 (95% CI: 0.64, 0.97) in former users with 20 prescriptions. In general, female former users had a slightly higher risk of gallstone disease than did male former users. Table 3 shows the odds ratios for patients with and without diabetes, obesity, and cardiovascular disease. These stratified analyses showed that the odds ratios were particularly reduced in the presence of these diseases. Among current statin users, those with a previous hospital diagnosis of diabetes had an adjusted odds ratio of 0.88 (95% CI: 0.77, 1.00), those with a previous hospital diagnosis of obesity had an adjusted odds ratio of 0.80 (95% CI: 0.64, 1.00), and those with a previous hospital diagnosis of cardiovascular disease had an adjusted odds ratio of 0.80 (95% CI: 0.74, 0.87). Our results were not impacted by a change in the split date for current and former users from 90 days to 30 or 180 days (results not shown). Table 4 shows that among patients with medium-term (1-2 years) and long-term (3 years) statin use, the association with gallstone disease was particularly protective. Furthermore, as the intensity of statin use increased, the association with gallstones decreased.
In cases with gallbladder surgery (n ¼ 744), we found that current statin users had an overall adjusted odds ratio of 0.88 (95% CI: 0.62, In the subanalysis of statin users in which those with 1-4 prescription were the reference group, we found an adjusted odds ratio of 0.76 (95% CI: 0.67, 0.86) for current statin users with 5-19 prescriptions and an adjusted odds ratio of 0.65 (95% CI: 0.56, 0.74) for current statin users with 20 prescriptions. For former statin users, the corresponding adjusted odds ratios were 0.78 (95% CI: 0.66, 0.92) and 0.64 (95% CI: 0.51, 0.80), respectively. In the final subanalysis, we found that statin users with no statin prescription 12 months before their index date had an adjusted odds ratio of 1.39 (95% CI: 1.19, 1.61) compared with continuing statin users.
When we divided the cases into the 7 statin preparation subtypes and also according to lipophilicity, we found no major heterogeneity of the odds ratios (results not shown). In the analysis of other lipid-lowering drugs, we identified 70 current users (0.2%) and 122 former users (0.4%) among cases and 377 current users (0.1%) and 775 former users (0.2%) among controls. For current users, this corresponded to an adjusted odds ratio of 1.42 (95% CI: 1.09, 1. 
DISCUSSION
In this population-based case-control study, current statin users had a decreased odds ratio for gallstone disease compared with nonusers, so long as they had 5 prescriptions. This duration corresponds to 1-2 years of statin use, dependent upon the intensity of the use. For former users, the decrease in odds ratios was less pronounced and present only after 20 prescriptions, but the sustained decrease in odds ratios in these patients may reflect a long-standing effect of statins in the prevention of gallstone disease. This pattern of results was insensitive to type or lipophilicity of statins, changes in the definition of current and former users (30 or 180 days vs. 90 days), and the restriction to cases with gallbladder surgery. In addition, patients who discontinued statin treatment 12 months before their index date had an increased odds ratio for gallstone disease compared with continuing statin users. As expected, we found no reduction in the odds ratio for gallstone disease in patients treated with other lipid-lowering drugs.
Our results extend the results of other studies (6) (7) (8) (22) (23) (24) . In 2009, Bodmer et al. (7) published a study that included 27,035 cases with gallstone disease treated with Abbreviations: CI, confidence interval; OR, odds ratio. a Controlled for age, county, sex, and period of diagnosis. b Controlled for the previous hospital discharges, diagnoses, and treatments mentioned in Table 1 and matched on age, county, sex, and period of diagnosis. The reference group was the number of statin users in each stratum.
cholecystectomy and 106,531 controls. The study was based on the UK General Practice Research Database, which was representative of the United Kingdom population in most aspects (9) , and was supported by results from another casecontrol study from Israel (8). Bodmer et al. found adjusted odds ratios similar ours (e.g., current users with 20 prescriptions had an adjusted odds ratio of 0.67 (95% CI: 0.55, 0.80)), and they had to some extent better confounder control (e.g., they controlled for body mass index and smoking status, although those data were ascertained close to the index date, rather than before the first statin prescription). However, the study (7) only included patients with severe gallstone-related complications and relied on information from general practitioners regarding the in-hospital procedure of cholecystectomy. (5) that included 830 patients undergoing gallbladder ultrasonography (of whom only 4.6% reported a previous statin use) did not find any association between statin use and gallstone disease. Moreover, reports on alterations in human bile cholesterol saturation after statin therapy showed compelling evidence that indicated that statins decreased the cholesterol saturation of bile (23, 24) , although results of a few reports did not confirm this association (25, 26) . Animal studies have also reported beneficial effects of statins in the prevention of gallstone formation (27, 28) .
The strengths of our study include the population-based design within a universal health care system with complete hospital and prescription history and access to appropriate population controls. In addition, our analysis adjusted for several important risk factors for gallstone disease.
Our study also has limitations. We used redeemed prescriptions as a surrogate for actual statin consumption, which may be imperfect. However, we stratified our analyses on the overall number of prescriptions, and therefore the possibility of including nonusers, at least among patients with several prescriptions, is minimal. The categorization of current and former statin users is also imperfect, and thus there might be current users in the group of former users and vice versa. The subanalysis in which we changed the split date for current and former users, however, supported the results of our main analysis. Furthermore, registry diagnoses may be inaccurate, and thus misclassification of gallstone disease could occur, although the overall quality and accuracy of the data in the NRP has been estimated to be high Abbreviations: CI, confidence interval; OR, odds ratio. a Short-, medium-, and long-term use were calculated using the time from first prescription to last prescription before date of gallstone disease or index date.
b Intensity was determined as number of pills prescribed divided by the time from first prescription to the date of gallstone disease or index date separated into 3 categories. (29) . The subanalysis of cases with gallbladder surgery was conducted to increase the positive predictive value of the diagnosis of gallstone disease (30) , and it confirmed our main finding. Moreover, we find it unlikely that misclassification of gallstone disease would be unequally distributed between statin users and nonusers, and thus any such misclassification would bias estimates of dichotomous exposure associations towards the null. However, the problem of misclassification would become evident in the stratified analysis of patients with and without a diagnosis of obesity (i.e., an obesity diagnosis registered in the NRP has a high positive predictive value but a low sensitivity). Hence, the odds ratios for gallstone disease in obese patients would reflect the ratios of the very obese, whereas those of patients without obesity would be measured by the overall estimate.
Diagnoses of asymptomatic or mild gallstone disease may be more likely among statin users than among nonusers because of the routine physical examination of statin users. This tendency would cause overestimation of the risk of gallstone disease among statin users compared with nonusers, and therefore statins may not explain the decreased odds ratios. Furthermore, the subanalysis of patients with gallbladder surgery (i.e., symptomatic cases), in which it seems unlikely that statin users would have a higher chance of being diagnosed, confirmed our main finding.
Another limitation is that the exposure group of statin users presumably differs from nonusers in aspects connected to an increased risk of gallstone disease, such as poor diet and physical inactivity. Hence, our results could have been confounded by indication, because new users of statins might also have improved their health behaviors. However, the results for other lipid-lowering drugs showed no decreasing risk of gallstone disease, although these associations would have been susceptible to the same confounding. Moreover, although we adjusted for differences in several important gallstone risk factors (or surrogates thereof), there may have been unmeasured confounding. This unmeasured confounding would arise from factors on which we did not have certain information, such as physical activity levels, socioeconomic status (although not strongly associated with statin use in Denmark (31)), and levels of triglycerides, as well as from poorly measured factors, such as obesity. However, these confounding factors all tend to be associated with an increased risk of gallstone disease, and thus may explain the increased risk of gallstone disease for statin users with 1-4 prescriptions but not the risk-reducing association with statin use of longer duration. Furthermore, by comparing statin users with 5-19 and 20 prescriptions with statin users with 1-4 prescriptions, we were able to reduce the potential for bias from some of these confounders, as they would be more similarly distributed in these 3 statin exposure groups than in a comparison between statins users and never users. A similar situation is present in the stratified analysis based on history of cardiovascular disease. In patients with a history of cardiovascular disease, these confounding factors were probably relatively equally distributed between cases and controls and thereby limited impact on the odds ratio, whereas they were more unequally distributed in patients with no history of cardiovascular disease.
As noted above, the initiation of statin treatment is sometimes also accompanied by changes in health behaviors, such as increased physical activity and eating a healthier diet. It is therefore possible that the decreased risk of gallstone disease associated with initiation of statin use was caused not only by statins but also by the beginning of health-seeking behaviors. Although we cannot rule out this confounding, our analysis comparing cases who discontinued statins with continuing statin users, which showed a higher risk among those who stopped statin therapy, supported the hypothesis that statins in fact do reduce the risk of gallstone disease directly. Furthermore, lifestyle factors were not found to be important confounders in the study by Tsai et al. (6) or the study by Bodmer et al. (7, 32) .
It is well-known that fibrates (included in the group of other lipid-lowering drugs in this study) increase the risk of gallstone disease (5), and our study supported this association. Because the residual and unmeasured confounding discussed above is expected to cause overestimation of the association between gallstone disease and these drugs, our results should not be taken alone as evidence of a potentially harmful effect. In conclusion, this population-based casecontrol study confirmed that long-term sustained statin use decreases the risk of gallstone disease in both men and women.
